O	0	3	The	The	DT	B-NP
O	4	14	semaphorin	semaphorin	NN	I-NP
O	15	17	7A	7A	NN	I-NP
O	18	26	receptor	receptor	NN	I-NP
O	27	33	Plexin	Plexin	NN	I-NP
O	34	36	C1	C1	NN	I-NP
O	37	39	is	be	VBZ	B-VP
O	40	44	lost	lose	VBN	I-VP
O	45	51	during	during	IN	B-PP
B-Cancer	52	60	melanoma	melanoma	NN	B-NP
O	61	71	metastasis	metastasis	NN	I-NP
O	71	72	.	.	.	O

O	73	76	The	The	DT	B-NP
O	77	91	transformation	transformation	NN	I-NP
O	92	94	of	of	IN	B-PP
O	95	101	normal	normal	JJ	B-NP
B-Cell	102	113	melanocytes	melanocyte	NNS	I-NP
O	113	114	,	,	,	O
O	115	117	or	or	CC	O
B-Cell	118	128	melanocyte	melanocyte	NN	B-NP
I-Cell	129	133	stem	stem	NN	I-NP
I-Cell	134	139	cells	cell	NNS	I-NP
O	139	140	,	,	,	O
O	141	143	to	to	TO	B-PP
B-Cancer	144	152	melanoma	melanoma	NN	B-NP
O	152	153	,	,	,	O
O	154	156	is	be	VBZ	B-VP
O	157	158	a	a	DT	B-NP
O	159	166	complex	complex	JJ	I-NP
O	167	174	process	process	NN	I-NP
O	175	184	involving	involve	VBG	B-VP
O	185	193	multiple	multiple	JJ	B-NP
O	194	204	mechanisms	mechanism	NNS	I-NP
O	204	205	.	.	.	O

O	206	210	Loss	Loss	NN	B-NP
O	211	213	of	of	IN	B-PP
B-Cancer	214	219	tumor	tumor	NN	B-NP
O	220	230	suppressor	suppressor	NN	I-NP
O	231	239	proteins	protein	NNS	I-NP
O	239	240	,	,	,	O
O	241	246	which	which	WDT	B-NP
O	247	255	function	function	VBP	B-VP
O	256	258	as	as	IN	B-PP
O	259	265	brakes	brake	NNS	B-NP
O	266	268	on	on	IN	B-PP
B-Cell	269	273	cell	cell	NN	B-NP
O	274	280	growth	growth	NN	I-NP
O	280	281	,	,	,	O
O	282	291	migration	migration	NN	B-NP
O	291	292	,	,	,	O
O	293	295	or	or	CC	O
B-Cell	296	300	cell	cell	NN	B-NP
O	301	309	survival	survival	NN	I-NP
O	309	310	,	,	,	O
O	311	314	was	be	VBD	B-VP
O	315	325	recognized	recognize	VBN	I-VP
O	326	331	early	early	RB	B-ADVP
O	332	334	on	on	IN	B-PP
O	335	337	as	as	IN	B-PP
O	338	340	an	an	DT	B-NP
O	341	350	important	important	JJ	I-NP
O	351	360	mechanism	mechanism	NN	I-NP
O	361	364	for	for	IN	B-PP
O	365	375	initiation	initiation	NN	B-NP
O	376	379	and	and	CC	I-NP
O	380	391	progression	progression	NN	I-NP
O	392	394	of	of	IN	B-PP
B-Cancer	395	403	melanoma	melanoma	NN	B-NP
O	403	404	.	.	.	O

O	405	416	Semaphorins	Semaphorin	NNS	B-NP
O	417	420	and	and	CC	O
O	421	426	their	their	PRP$	B-NP
O	427	434	cognate	cognate	JJ	I-NP
O	435	444	receptors	receptor	NNS	I-NP
O	444	445	,	,	,	I-NP
O	446	453	Plexins	Plexin	NNS	I-NP
O	454	457	and	and	CC	I-NP
O	458	469	neuropilins	neuropilin	NNS	I-NP
O	469	470	,	,	,	O
O	471	474	are	be	VBP	B-VP
O	475	483	involved	involve	VBN	I-VP
O	484	486	in	in	IN	B-PP
B-Cell	487	495	neuronal	neuronal	JJ	B-NP
O	496	507	pathfinding	pathfinding	NN	I-NP
O	507	508	,	,	,	O
O	509	515	immune	immune	JJ	B-NP
O	516	524	function	function	NN	I-NP
O	524	525	,	,	,	O
O	526	529	and	and	CC	O
B-Cancer	530	535	tumor	tumor	NN	B-NP
O	536	547	progression	progression	NN	I-NP
O	548	555	through	through	IN	B-PP
O	556	563	effects	effect	NNS	B-NP
O	564	566	on	on	IN	B-PP
B-Multi-tissue_structure	567	572	blood	blood	NN	B-NP
I-Multi-tissue_structure	573	579	vessel	vessel	NN	I-NP
O	580	586	growth	growth	NN	I-NP
O	587	590	and	and	CC	O
B-Cell	591	595	cell	cell	NN	B-NP
O	596	605	migration	migration	NN	I-NP
O	605	606	.	.	.	O

O	607	617	Semaphorin	Semaphorin	NN	B-NP
O	618	620	7A	7A	NN	I-NP
O	621	622	(	(	(	O
O	622	628	Sema7A	Sema7A	NN	B-NP
O	628	629	)	)	)	O
O	630	632	is	be	VBZ	B-VP
O	633	634	a	a	DT	B-NP
B-Cellular_component	635	643	membrane	membrane	NN	I-NP
O	643	644	-	-	HYPH	B-VP
O	644	650	linked	link	VBN	B-NP
O	651	661	semaphorin	semaphorin	NN	I-NP
O	662	666	that	that	WDT	B-NP
O	667	669	is	be	VBZ	B-VP
O	670	679	expressed	express	VBN	I-VP
O	680	682	by	by	IN	B-PP
O	683	688	human	human	JJ	B-NP
B-Cell	689	702	keratinocytes	keratinocyte	NNS	I-NP
O	702	703	,	,	,	O
O	704	707	and	and	CC	O
O	708	710	we	we	PRP	B-NP
O	711	715	have	have	VBP	B-VP
O	716	721	shown	show	VBN	I-VP
O	722	726	that	that	IN	B-SBAR
O	727	733	Sema7A	Sema7A	NN	B-NP
O	734	739	binds	bind	VBZ	B-VP
O	740	742	to	to	TO	B-PP
O	743	748	human	human	JJ	B-NP
B-Cell	749	760	melanocytes	melanocyte	NNS	I-NP
O	761	768	through	through	IN	B-PP
O	769	774	beta1	beta1	NN	B-NP
O	774	775	-	-	HYPH	B-NP
O	775	784	integrins	integrin	NNS	I-NP
O	785	788	and	and	CC	O
O	789	792	the	the	DT	B-NP
O	793	799	Plexin	Plexin	NN	I-NP
O	800	802	C1	C1	NN	I-NP
O	803	811	receptor	receptor	NN	I-NP
O	811	812	.	.	.	O

O	813	823	Functional	Functional	JJ	B-NP
O	824	831	studies	study	NNS	I-NP
O	832	838	showed	show	VBD	B-VP
O	839	843	that	that	IN	B-SBAR
O	844	850	Sema7A	Sema7A	NN	B-NP
O	851	861	stimulates	stimulate	VBZ	B-VP
B-Cellular_component	862	874	cytoskeletal	cytoskeletal	JJ	B-NP
O	875	889	reorganization	reorganization	NN	I-NP
O	890	892	in	in	IN	B-PP
O	893	898	human	human	JJ	B-NP
B-Cell	899	910	melanocytes	melanocyte	NNS	I-NP
O	910	911	,	,	,	O
O	912	921	resulting	result	VBG	B-VP
O	922	924	in	in	IN	B-PP
O	925	933	adhesion	adhesion	NN	B-NP
O	934	937	and	and	CC	I-NP
B-Cellular_component	938	946	dendrite	dendrite	NN	I-NP
O	947	956	formation	formation	NN	I-NP
O	956	957	.	.	.	O

O	958	968	Downstream	Downstream	JJ	B-NP
O	969	976	targets	target	NNS	I-NP
O	977	979	of	of	IN	B-PP
O	980	986	Plexin	Plexin	NN	B-NP
O	987	989	C1	C1	NN	I-NP
O	990	999	signaling	signaling	NN	I-NP
O	1000	1002	in	in	IN	B-PP
O	1003	1008	human	human	JJ	B-NP
B-Cell	1009	1020	melanocytes	melanocyte	NNS	I-NP
O	1021	1028	include	include	VBP	B-VP
O	1029	1036	cofilin	cofilin	NN	B-NP
O	1037	1040	and	and	CC	O
O	1041	1044	LIM	LIM	NN	B-NP
O	1045	1051	kinase	kinase	NN	I-NP
O	1052	1054	II	II	CD	I-NP
O	1054	1055	,	,	,	O
O	1056	1060	both	both	DT	B-NP
O	1061	1063	of	of	IN	B-PP
O	1064	1069	which	which	WDT	B-NP
O	1070	1073	are	be	VBP	B-VP
O	1074	1082	critical	critical	JJ	B-NP
O	1083	1092	mediators	mediator	NNS	I-NP
O	1093	1095	of	of	IN	B-PP
B-Cell	1096	1100	cell	cell	NN	B-NP
O	1101	1109	adhesion	adhesion	NN	I-NP
O	1110	1113	and	and	CC	I-NP
O	1114	1123	migration	migration	NN	I-NP
O	1123	1124	.	.	.	O

O	1125	1127	In	In	IN	B-PP
O	1128	1132	this	this	DT	B-NP
O	1133	1139	report	report	NN	I-NP
O	1139	1140	,	,	,	O
O	1141	1143	we	we	PRP	B-NP
O	1144	1152	analyzed	analyze	VBD	B-VP
O	1153	1156	the	the	DT	B-NP
O	1157	1167	expression	expression	NN	I-NP
O	1168	1170	of	of	IN	B-PP
O	1171	1177	Plexin	Plexin	NN	B-NP
O	1178	1180	C1	C1	NN	I-NP
O	1181	1186	using	use	VBG	B-VP
O	1187	1207	immunohistochemistry	immunohistochemistry	NN	B-NP
O	1208	1210	on	on	IN	B-PP
B-Cancer	1211	1219	sections	section	NNS	B-NP
O	1220	1222	of	of	IN	B-PP
B-Cancer	1223	1230	primary	primary	JJ	B-NP
O	1231	1234	and	and	CC	I-NP
O	1235	1242	matched	matched	JJ	I-NP
B-Cancer	1243	1253	metastatic	metastatic	JJ	I-NP
I-Cancer	1254	1261	lesions	lesion	NNS	I-NP
O	1262	1266	from	from	IN	B-PP
O	1267	1269	19	19	CD	B-NP
O	1270	1278	subjects	subject	NNS	I-NP
O	1279	1282	and	and	CC	B-PP
O	1283	1285	in	in	IN	B-PP
O	1286	1287	a	a	DT	B-NP
O	1288	1293	large	large	JJ	I-NP
B-Cancer	1294	1302	melanoma	melanoma	NN	I-NP
I-Cancer	1303	1308	tumor	tumor	NN	I-NP
O	1309	1319	microarray	microarray	NN	I-NP
O	1319	1320	.	.	.	O

O	1321	1324	Our	Our	PRP$	B-NP
O	1325	1329	data	datum	NNS	I-NP
O	1330	1334	show	show	VBP	B-VP
O	1335	1336	a	a	DT	B-NP
O	1337	1348	significant	significant	JJ	I-NP
O	1349	1353	loss	loss	NN	I-NP
O	1354	1356	of	of	IN	B-PP
O	1357	1363	Plexin	Plexin	NN	B-NP
O	1364	1366	C1	C1	NN	I-NP
O	1367	1369	in	in	IN	B-PP
B-Cancer	1370	1380	metastatic	metastatic	JJ	B-NP
I-Cancer	1381	1389	melanoma	melanoma	NN	I-NP
O	1390	1398	compared	compare	VBN	B-PP
O	1399	1403	with	with	IN	B-PP
B-Cancer	1404	1411	primary	primary	JJ	B-NP
I-Cancer	1412	1420	melanoma	melanoma	NN	I-NP
O	1420	1421	,	,	,	O
O	1422	1432	suggesting	suggest	VBG	B-VP
O	1433	1436	the	the	DT	B-NP
O	1437	1448	possibility	possibility	NN	I-NP
O	1449	1453	that	that	IN	B-SBAR
O	1454	1457	the	the	DT	B-NP
O	1458	1464	Plexin	Plexin	NN	I-NP
O	1465	1467	C1	C1	NN	I-NP
O	1468	1476	receptor	receptor	NN	I-NP
O	1477	1479	is	be	VBZ	B-VP
O	1480	1481	a	a	DT	B-NP
B-Cancer	1482	1487	tumor	tumor	NN	I-NP
O	1488	1498	suppressor	suppressor	NN	I-NP
O	1499	1506	protein	protein	NN	I-NP
O	1507	1510	for	for	IN	B-PP
B-Cancer	1511	1519	melanoma	melanoma	NN	B-NP
O	1519	1520	.	.	.	O

